-
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax
Tuesday, September 28, 2021 - 8:24am | 350The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project BioShield contract. Related Link: Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection. The option...
-
Altimmune's Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers
Thursday, April 1, 2021 - 8:58am | 247Altimmune Inc (NASDAQ: ALT) has reported data from Phase 1b trial evaluating its NasoShield intranasal anthrax vaccine candidate. The 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers. The trial was conducted with...
-
How Altimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic'
Friday, June 23, 2017 - 8:15am | 1260Over the next 20 to 30 years, the world will suffer a pandemic with the potential “to bring humanity to its knees,” epidemiologist Larry Brilliant, M.D., told CNN in April. He was talking about new strains of influenza found in birds across the world. Yes, it’s the flu — not...
-
Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger
Thursday, April 6, 2017 - 4:01pm | 1947A few months ago, PharmAthene, Inc. (NYSE: PIP) and Altimmune announced they were merging in an all-stock transaction to create an integrated and diversified immunotherapeutics company. PharmAthene shareholders will decide whether the merger actually goes through on May 4. Ahead of the vote, and...
-
Maxim Analyst Issues Update On Tekmira's Ebola Research Development
Monday, April 13, 2015 - 9:58am | 290In a report published Monday, Maxim Group analyst Jason Kolbert commented on Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)'s ongoing research into the Ebola virus. Tekmira is part of an international consortium known as the International Severe Acute Respiratory and Emerging Infection Consortium (...